Previous 10 | Next 10 |
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8 th Annual Dawson Ja...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’...
2023-09-11 09:49:45 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay NovaBay Pharmaceuticals, Inc. ( NBY ) Q2 2023 Earnings Call Transcript For further details...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the...
MONTRÉAL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- NioBay Metals inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the start of a drilling campaign on the Crevier Property, which is owned by Les Minéraux Crevier Inc, of which NioBay...
2023-08-10 16:10:51 ET NovaBay press release ( NYSE: NBY ): Q2 GAAP EPS of -$1.27 misses by $0.71 . Revenue of $4.61M (+28.1% Y/Y) beats by $0.94M . For further details see: NovaBay GAAP EPS of -$1.27 misses by $0.71, revenue of $4.61M beats by $0.94M
Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-ye...
2023-08-09 17:35:09 ET NovaBay ( NYSE: NBY ) is scheduled to announce Q2 earnings results on Thursday, August 10th, after market close. The consensus EPS Estimate is -$0.56 and the consensus Revenue Estimate is $3.67M (+20.7% Y/Y). Over the last 3 months, EPS estimates...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova ® -branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awarene...
MONTRÉAL, June 27, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that, following the start of exploration work on the Foothills project, assay results confirm the presence of high TiO 2 ...